Azathioprine
Treatment for Interstitial lung disease and pulmonary sarcoidosis
Typical Dosage: 1-2.5 mg/kg daily
Effectiveness
58%
Safety Score
30%
Clinical Trials
1
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
30
DangerousModerateSafe
Treatment Details
Dosage Range
1-2.5 mg/kg daily
Time to Effect
3-6 months
Treatment Duration
1-2 years (or longer)
Evidence Quality
MODERATEConfidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$1,250
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
Outcome-Based Costs
Cost per Responder
$2,083
Cost per Remission
$4,167
Azathioprine Outcomes
for Interstitial lung disease and pulmonary sarcoidosis
Efficacy Outcomes
Overall Effectiveness
+58%
Response Rate
+60%
Remission Rate
+30%
Common Side Effects
Nausea
+15%
Vomiting
+8%
Myelosuppression
+5%
Liver enzyme elevation
+8%
Increased infection risk
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov